NEXT PHARMA
Pharmaceutical company · 5 brands · 7 molecules
Ranked #52 of 81 companies in Angiotensin-Ii Antagonists, Combinations
Company overview
NEXT PHARMA is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 5 product registrations across 7 distinct molecules. Its portfolio is concentrated in Angiotensin-Ii Antagonists, Combinations and Cardiac Care. It has no DRAP recall, shortage or safety notices on record.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Products by NEXT
1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.
Top molecules by brand count
Therapeutic classes
Conditions treated
Price band (DRAP official ceilings)
Regulatory record
No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for NEXT
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included